Samsung Bioepis and Phrontline Biopharma Enter Global Collaboration to Advance Next-Generation Antibody-Drug Conjugates for Solid Tumors Samsung Bioepis Co., Ltd., a leading global biopharmaceutical company, and Phrontline Biopharma, a clinical-stage biotechnology firm pioneering a new generation of Antibody-Drug Conjugates (ADCs),…
IFF and BASF Launch Strategic Collaboration to Advance Next-Generation Enzyme and Polymer Technologies International Flavors & Fragrances Inc. (IFF), a global leader in flavors, fragrances, food ingredients, health, and biosciences, has announced a strategic collaboration with BASF, one of the…
StratifAI Selected for MSK iHub Challenge 2025 Cohort to Accelerate Polaris™ Validation Using World-Class Clinical Datasets StratifAI, the AI-driven precision oncology company behind the Polaris™ platform, today announced its selection for the prestigious Memorial Sloan Kettering (MSK) iHub Challenge 2025…
the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for Quantum Technologies, Q-Alliance…
a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered into a royalty financing agreement with DRI Healthcare Acquisitions LP (DRI) and accelerated its timelines for the submission of…
IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its role as a founding member of Q-Alliance, an ambitious new initiative to establish a world-class quantum computing hub in Lombardy, Italy. Formed in alignment with Italy’s National Strategy for…
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced the appointment of Thomas Fuchs as CEO. Thomas will lead the Company to advance its pipeline of proprietary drug…
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing…
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 EURneffy® 2 mg nasal spray offers a…
Life Sciences BC has revealed the companies and mentors selected for its 2026 Investor Readiness Program (IRP), a six-month initiative designed to help emerging life sciences ventures in British Columbia attract investment, refine their business strategies, and accelerate growth. Now…